Insilico is building in silico cells for Evonik Industries

28 November 2008

Insilico Biotechnology AG announces a multi-year collaboration with Evonik Industries, a global leader in systems-oriented development of industrial fermentations. The Stuttgart-based company provides its platform and expertise for building and simulating in silico bacterial strains. read more

Insilico expands collaboration with Kluyver Centre for Genomics of Industrial Fermentation

22 January 2008

Insilico Biotechnology AG announces a continued collaboration with the Netherlands’ Kluyver Centre, a joint industry and academic consortium that applies genomics technology for improving industrial fermentation. The Stuttgart based company provides its new steady state and dynamic modeling and simulation platform for the set-up and analysis of predictive metabolic network models. read more

Threefold Promotion: Insilico and BioIndustry 2021

17 October 2007

Insilico Biotechnology AG is partner in three out of five clusters belonging to the new research initiative entitled »BioIndustry 2021« which aims at meeting the oncoming challenges facing today’s society — first and foremost changes in climate followed by the ever increasing lack of resources — with innovative projects from the field of white biotechnology.

Insilico’s focus is on networking. Together with other partners from industry and research institutions, Insilico is playing an active role in BioIndustry 2021. The German Ministry of Education and Research (BMBF) is supporting this initiative with 60 million € in order to turn research ideas from the field of white biotechnology into products for marketing as soon as possible. The Ministry’s major goal here is to make Germany one of the most attractive sites in the world for biosciences. read more

Insilico is designing Formula One-type bacteria

21 August 2007

Insilico Biotechnology AG in multi-year collaboration with Wacker Chemie AG to design high-performance bacterial strains

Insilico Biotechnology AG is set to become one of the partners in the GenoMik-Plus network. The Stuttgart-based company will provide the partners of the research consortium with network models and simulations of the bacterial metabolism. The objective is to develop high-performance bacterial strains that produce large amounts of useful substances.

© BIOPRO Baden-Württemberg GmbH, Article first published at, the Biotech/Life Sciences Portal of the state Baden-Württemberg. All rights reserved. read more

Virtual Liver Cells Optimize Drug Development

19 July 2007

Insilico Biotechnology AG from Stuttgart with new funding for systems biology research from the German Federal Ministry of Education and Research (BMBF)

Since 2005, Insilico Biotechnology AG as an industrial partner in the federal HepatoSys competence network has been performing computer-based mapping and testing of liver cell metabolism. As a service provider in the systems biology sector, Insilico is responsible in particular for determining kinetic parameters using supercomputers. The aim is to model a »virtual liver cell« to enable physiological cell processes — such as the breakdown of drugs and toxic substances — to be followed »in silico«, i.e. on the computer. For the second project phase, this Stuttgart-based life science company is receiving Euro 250,000 of funding in the next three years. read more